Cancer-testis antigens are commonly expressed in multiple myeloma and induce systemic immunity following allogeneic stem cell transplantation.

Immunotherapies using cancer-testis (CT) antigens as targets represent a potentially useful treatment in patients with multiple myeloma (MM) who commonly show recurrent disease following chemotherapy. We analyzed the expression of 11 CT antigens in bone marrow samples from patients with MM (n=55) and healthy donors (n=32) using reverse transcriptase-polymerase chain reaction (RT-PCR). CT antigens were frequently expressed in MM with 56% (MAGEC2), 55% (MAGEA3), 35% (SSX1), 20% (SSX4, SSX5), 16% (SSX2), 15% (BAGE), 7% (NY-ESO-1), and 6% (ADAM2, LIPI) expressing the given antigen. Importantly, CT antigens were not expressed in healthy bone marrow. Analyzing patients with MM (n=66) for antibody responses against MAGEA3, SSX2, and NY-ESO-1, we found strong antibody responses against CT antigens preferentially in patients who had received allogeneic stem cell transplantation (alloSCT). Antibody responses against NY-ESO-1 correlated with NY-ESO-1-specific CD4+ and CD8+ T-cell responses against peptide NY-ESO-1(51-62) and CD4+ responses against NY-ESO-1(121-140) in 1 of these patients. These allogeneic immune responses were not detectable in pretransplantation samples and in the patients' stem cell donors, indicating that CT antigens might indeed represent natural targets for graft-versus-myeloma effects. Immune responses induced by alloSCT could be boosted by active CT antigen-specific immunotherapy, which might help to achieve long-lasting remissions in patients with MM.

[1]  R. Kyle,et al.  Multiple myeloma. , 2008, Blood.

[2]  M. Pfreundschuh,et al.  Prospective study on the expression of cancer testis genes and antibody responses in 100 consecutive patients with primary breast cancer , 2006, International journal of cancer.

[3]  A. Simpson,et al.  Generation of monoclonal antibodies to cancer/testis (CT) antigen CT10/MAGE-C2. , 2006, Cancer immunity.

[4]  P. Moss,et al.  CD8+ T cells specific for cancer germline gene antigens are found in many patients with multiple myeloma, and their frequency correlates with disease burden. , 2005, Blood.

[5]  J. Keats,et al.  SSX Cancer Testis Antigens are Expressed in Most Multiple Myeloma Patients: Co-Expression of SSX1, 2, 4, and 5 Correlates With Adverse Prognosis and High Frequencies of SSX-Positive PCs , 2005, Journal of immunotherapy.

[6]  Eleanor Woodward,et al.  Microarray analysis of tumour antigen expression in presentation acute myeloid leukaemia. , 2005, Biochemical and biophysical research communications.

[7]  Yao-Tseng Chen,et al.  The cancer-testis antigens CT7 (MAGE-C1) and MAGE-A3/6 are commonly expressed in multiple myeloma and correlate with plasma-cell proliferation. , 2005, Blood.

[8]  F. Zhan,et al.  NY-ESO-1 is highly expressed in poor-prognosis multiple myeloma and induces spontaneous humoral and cellular immune responses. , 2005, Blood.

[9]  A. Kiani,et al.  T cell-mediated graft-versus-leukemia reactions after allogeneic stem cell transplantation , 2005, Cancer Immunology, Immunotherapy.

[10]  B. Brodin,et al.  Cancer/testis antigen expression in human mesenchymal stem cells: down-regulation of SSX impairs cell migration and matrix metalloproteinase 2 expression. , 2005, Cancer research.

[11]  Lai Wei,et al.  Expression of cancer/testis (CT) antigens in Chinese hepatocellular carcinoma and its correlation with clinical parameters. , 2005, Cancer letters.

[12]  J. Gu,et al.  Expression Profile of Cancer-Testis Genes in 121 Human Colorectal Cancer Tissue and Adjacent Normal Tissue , 2005, Clinical Cancer Research.

[13]  C. Klebanoff,et al.  Sinks, suppressors and antigen presenters: how lymphodepletion enhances T cell-mediated tumor immunotherapy. , 2005, Trends in immunology.

[14]  Andreas Radbruch,et al.  Maintenance of serum antibody levels. , 2005, Annual review of immunology.

[15]  R. Kyle,et al.  Drug therapy: Multiple myeloma , 2004 .

[16]  S. Rosenberg,et al.  Cancer regression in patients with metastatic melanoma after the transfer of autologous antitumor lymphocytes , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[17]  H. Einsele,et al.  Deletion of chromosome band 13q14 as detected by fluorescence in situ hybridization is a prognostic factor in patients with multiple myeloma who are receiving allogeneic dose-reduced stem cell transplantation. , 2004, Blood.

[18]  P. Coulie,et al.  Two new tumor‐specific antigenic peptides encoded by gene MAGE‐C2 and presented to cytolytic T lymphocytes by HLA‐A2 , 2004, International journal of cancer.

[19]  Yao-Tseng Chen,et al.  Vaccine-Induced CD4+ T Cell Responses to MAGE-3 Protein in Lung Cancer Patients1 , 2004, The Journal of Immunology.

[20]  H. Döhner,et al.  mRNA expression of leukemia‐associated antigens in patients with acute myeloid leukemia for the development of specific immunotherapies , 2004, International journal of cancer.

[21]  A. Simpson,et al.  The cancer/testis genes: review, standardization, and commentary. , 2004, Cancer immunity.

[22]  R. Storb,et al.  Non-myeloablative hematopoietic cell transplantation as immunotherapy for hematologic malignancies. , 2003, Cancer treatment reviews.

[23]  X. Qian,et al.  HCA587 Antigen Expression in Normal Tissues and Cancers: Correlation with Tumor Differentiation in Hepatocellular Carcinoma , 2003, Laboratory Investigation.

[24]  Yao-Tseng Chen,et al.  Survey of naturally occurring CD4+ T cell responses against NY-ESO-1 in cancer patients: Correlation with antibody responses , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[25]  M. Pfreundschuh,et al.  Expression of serologically identified tumor antigens in acute leukemias. , 2003, Leukemia research.

[26]  D. Atanackovic,et al.  Monitoring CD4+ T cell responses against viral and tumor antigens using T cells as novel target APC. , 2003, Journal of immunological methods.

[27]  Kenneth C. Anderson,et al.  Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group , 2003, British journal of haematology.

[28]  M. Chiriva-Internati,et al.  Gene expression and immunologic consequence of SPAN-Xb in myeloma and other hematologic malignancies. , 2003, Blood.

[29]  J. Teruya-Feldstein,et al.  Expression of cancer/testis (CT) antigens MAGE-A1, MAGE-A3, MAGE-A4, CT-7, and NY-ESO-1 in malignant gammopathies is heterogeneous and correlates with site, stage and risk status of disease. , 2003, Cancer immunity.

[30]  B. Czepulkowski,et al.  Frequent expression of HAGE in presentation chronic myeloid leukaemias , 2002, Leukemia.

[31]  A. Burgess,et al.  Large Scale Identification of Human Hepatocellular Carcinoma-Associated Antigens by Autoantibodies1 , 2002, The Journal of Immunology.

[32]  R. Bleackley,et al.  Cytotoxic T lymphocytes: all roads lead to death , 2002, Nature Reviews Immunology.

[33]  V. Brusic,et al.  NY-ESO-1 119-143 is a promiscuous major histocompatibility complex class II T-helper epitope recognized by Th1- and Th2-type tumor-reactive CD4+ T cells. , 2002, Cancer research.

[34]  K. Bumm,et al.  MAGE‐C1 (CT7) gene expression in multiple myeloma: relationship to sperm protein 17 , 2001, European journal of haematology.

[35]  N. Altorki,et al.  Immunohistochemical analysis of NY‐ESO‐1 antigen expression in normal and malignant human tissues , 2001, International journal of cancer.

[36]  R. Schreiber,et al.  IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity , 2001, Nature.

[37]  Lloyd J. Old,et al.  and shape tumour immunogenicity , 2001 .

[38]  V. Cerundolo,et al.  Strategy for monitoring T cell responses to NY-ESO-1 in patients with any HLA class I allele. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[39]  J. Trapani,et al.  Perforin-Mediated Cytotoxicity Is Critical for Surveillance of Spontaneous Lymphoma , 2000, The Journal of experimental medicine.

[40]  V Brusic,et al.  NY-ESO-1 encodes DRB1*0401-restricted epitopes recognized by melanoma-reactive CD4+ T cells. , 2000, Cancer research.

[41]  S. Rosenberg,et al.  Identification of CD4+ T Cell Epitopes from NY-ESO-1 Presented by HLA-DR Molecules , 2000, The Journal of Immunology.

[42]  T. Boon,et al.  MAGE‐B5, MAGE‐B6, MAGE‐C2, and MAGE‐C3: four new members of the MAGE family with tumor‐specific expression , 2000, International journal of cancer.

[43]  N. Altorki,et al.  Expression of cancer-testis antigens in lung cancer: definition of bromodomain testis-specific gene (BRDT) as a new CT gene, CT9. , 2000, Cancer letters.

[44]  Yao-Tseng Chen,et al.  CT10: A new cancer‐testis (CT) antigen homologous to CT7 and the MAGE family, identified by representational‐difference analysis , 2000, International journal of cancer.

[45]  R. Bataille,et al.  The cancer germ‐line genes MAGE‐1, MAGE‐3 and PRAME are commonly expressed by human myeloma cells , 2000, European journal of immunology.

[46]  D. Jäger,et al.  Identification of Ny-Eso-1 Epitopes Presented by Human Histocompatibility Antigen (Hla)-Drb4*0101–0103 and Recognized by Cd4+T Lymphocytes of Patients with Ny-Eso-1–Expressing Melanoma , 2000, The Journal of experimental medicine.

[47]  Yao-Tseng Chen,et al.  Expression of MAGE‐antigens in normal tissues and cancer , 2000, International journal of cancer.

[48]  V. Brusic,et al.  NY-ESO-1 Encodes DRB 1 * 0401-restricted Epitopes Recognized by Melanoma-reactive CD 4 1 T Cells 1 , 2000 .

[49]  E. Owen-Jones,et al.  Expression of testicular genes in haematological malignancies , 1999, British Journal of Cancer.

[50]  D. Jäger,et al.  Humoral immune responses of cancer patients against “Cancer‐Testis” antigen NY‐ESO‐1: Correlation with clinical events , 1999 .

[51]  F. Brasseur,et al.  Genes encoding tumor-specific antigens are expressed in human myeloma cells. , 1999, Blood.

[52]  S. Rosenberg,et al.  A breast and melanoma-shared tumor antigen: T cell responses to antigenic peptides translated from different open reading frames. , 1998, Journal of immunology.

[53]  Lloyd J. Old,et al.  A Survey of the Humoral Immune Response of Cancer Patients to a Panel of Human Tumor Antigens , 1998, The Journal of experimental medicine.

[54]  F. Gudat,et al.  Identification and intracellular location of MAGE-3 gene product. , 1995, Cancer research.